First and only PARP inhibitor to improve invasive disease-free survival in patients
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Prostate cancer is the second-most common cancer in men and despite an increase in the number of available treatments for men with mCRPC, five-year survival remains low
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Subscribe To Our Newsletter & Stay Updated
